Front Row Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Front Row Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16	Closed	-$1K	–	934
2019 Q2	$1K	Hold	16	–	–	﹤0.01%	932
2019 Q1	$1K	Hold	16	–	–	﹤0.01%	936
2018 Q4	$1K	Hold	16	–	–	﹤0.01%	911
2018 Q3	$1	Hold	16	–	–	﹤0.01%	881
2018 Q2	$2	Buy	+16	New	+$1.4K	﹤0.01%	825
2018 Q1	–	Sell	-7,951	Closed	-$709K	–	947
2017 Q4	$709K	Buy	+7,951	New	+$691K	0.56%	55

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Front Row Advisors's BMRN Position: Q3 2019 in Review

Front Row Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 16 shares — an estimated $1K sold.

Front Row Advisors first reported a position in BMRN in Q4 2017 and held it in 6 quarters. The position peaked at $709K in Q4 2017. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Front Row Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Front Row Advisors sold 16 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $1K.
Front Row Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Front Row Advisors's BioMarin Pharmaceuticals position peaked at $709K in Q4 2017.
436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Front Row Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.